Lonza Obtains Order Preventing Infringement Of Its Patents Covering The Cocoon Platform

• On January 21, 2022, a United States federal district court entered a preliminary injunction preventing infringement of Lonza’s patents related to its innovative Cocoon Platform
• Adva Biotechnology Ltd. is enjoined from making, using, selling, offering to sell, and importing into the United States the Adva X3 system pending resolution of the case

On January 21, 2022, in the United States District Court for the District of Maryland, Lonza, a leading global cell and gene therapy manufacturer, obtained a preliminary injunction against Adva Biotechnology Ltd. (“Adva”) preventing Adva from importing and offering their Adva X3 device in the United States pending resolution of the case.

On October 23, 2020, Lonza brought suit against Adva, alleging Adva’s infringement of Lonza and their affiliate Octane Biotech Inc.’s patents covering the innovative Cocoon Platform. The Cocoon Platform is an automated and closed platform for patient-scale cell therapy manufacturing, designed to overcome manufacturing challenges associated with patient-scale personalized medicines. The Cocoon Platform is commercially available and gaining global traction as the go-to manufacturing platform for patient-scale cell therapies.

According to Lonza’s court filings, Adva’s system—the ADVA X3—infringes Lonza and Octane Biotech Inc.’s patents including U.S. Patent Nos. 10,844,338; 10,723,986; 9,783,768; 9,701,932; 9,534,195; 9,499,780; and 8,492,140. Details of the case can be found at case number 8:20-cv-03099-PX. With this order, Lonza further demonstrates its position as a leading innovator in the cell therapy manufacturing market and will continue to provide its leading solutions to therapy developers and ultimately to patients.

As a leading innovator in the pharmaceutical and biologics manufacturing industry, Lonza has many patents covering their innovative offerings.

For more information on Lonza’s patent portfolio please visit www.lonza.com/ip.

About Lonza
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 15,000 employees, we comprise high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 2.5 billion with a CORE EBITDA of CHF 847 million in H1 2021. For more information, visit www.lonza.com.